Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310221 | 0.81 | PDE5A (0.32) | PDE5ACA12CA1CA2CA9 | |
| SCHEMBL9331694 | 0.70 | ADH1B (0.41) | PDE5ABCHEACHECA12CA1 | |
| SCHEMBL9328724 | 0.69 | ADH1B (0.43) | PDE5ABCHEACHECA12CA1 | |
| SCHEMBL677205 | 0.67 | ADH1B (0.41) | BCHEACHECA12CA1CA2 | |
| SCHEMBL1220763 | 0.66 | CA12 (0.48) | CA12CA1CA2CA4CA9 | |
| SCHEMBL8261445 | 0.65 | BCHE (0.40) | BCHEACHECA12CA1CA2 | |
| SCHEMBL3304062 | 0.65 | BCHE (0.36) | BCHEACHECA12CA1CA2 | |
| SCHEMBL21291571 | 0.64 | CA12 (0.41) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13685929 | 0.64 | CA12 (0.41) | CA12CA1CA2CA4CA9 | |
| SCHEMBL399991 | 0.64 | ALDH1A1 (0.48) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2125695-A2 | NITRIC OXIDE DONOR COMPOUNDS | Nicox S.A. (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PDE5A 72/4885BCHE 2821/4885ACHE 394/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PDE5A 61/4885BCHE 2693/4885ACHE 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.